[SUNWAY] YoY Annualized Quarter Result on 31-Dec-2019 [#4]

Stock
[SUNWAY] SUNWAY BERHAD
Announcement Date
25-Feb-2020
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
31-Dec-2019 [#4]
Profit Trend
QoQ- 1.53%
YoY- 16.33%
Quarter Report
Latest QR
Upcoming QR
SUNWAY's Result
SUNWAY's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Revenue 5,194,951 3,714,168 3,833,310 4,780,447 5,410,283 5,374,834 4,655,592 1.84%
PBT 919,791 465,710 509,288 914,232 850,644 882,188 858,992 1.14%
Tax -166,951 2,274,341 -101,977 -78,294 -121,637 -149,369 -140,394 2.92%
NP 752,840 2,740,051 407,311 835,938 729,007 732,819 718,598 0.77%
-
NP to SH 676,691 2,665,443 359,600 766,633 658,991 639,513 585,883 2.42%
-
Tax Rate 18.15% -488.36% 20.02% 8.56% 14.30% 16.93% 16.34% -
Total Cost 4,442,111 974,117 3,425,999 3,944,509 4,681,276 4,642,015 3,936,994 2.03%
-
Net Worth 12,555,068 12,027,040 10,034,321 8,238,145 8,348,157 7,644,295 3,029,205 26.72%
Dividend
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Div 322,676 146,671 77,187 440,983 345,574 288,463 101,624 21.22%
Div Payout % 47.68% 5.50% 21.46% 57.52% 52.44% 45.11% 17.35% -
Equity
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Net Worth 12,555,068 12,027,040 10,034,321 8,238,145 8,348,157 7,644,295 3,029,205 26.72%
NOSH 4,934,079 4,934,074 4,933,931 4,933,931 4,924,402 4,918,491 1,954,326 16.68%
Ratio Analysis
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
NP Margin 14.49% 73.77% 10.63% 17.49% 13.47% 13.63% 15.44% -
ROE 5.39% 22.16% 3.58% 9.31% 7.89% 8.37% 19.34% -
Per Share
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
RPS 88.55 63.31 74.49 98.65 111.47 111.80 238.22 -15.19%
EPS 10.66 45.43 7.25 14.61 13.53 13.29 12.85 -3.06%
DPS 5.50 2.50 1.50 9.10 7.12 6.00 5.20 0.93%
NAPS 2.14 2.05 1.95 1.70 1.72 1.59 1.55 5.52%
Adjusted Per Share Value based on latest NOSH - 4,933,931
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
RPS 90.60 64.77 66.85 83.37 94.35 93.73 81.19 1.84%
EPS 11.80 46.48 6.27 13.37 11.49 11.15 10.22 2.42%
DPS 5.63 2.56 1.35 7.69 6.03 5.03 1.77 21.26%
NAPS 2.1896 2.0975 1.7499 1.4367 1.4559 1.3331 0.5283 26.72%
Price Multiplier on Financial Quarter End Date
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Date 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 -
Price 1.62 1.72 1.61 1.80 1.47 1.63 3.03 -
P/RPS 1.83 2.72 2.16 1.82 1.32 1.46 1.27 6.27%
P/EPS 14.05 3.79 23.04 11.38 10.83 12.25 10.11 5.63%
EY 7.12 26.41 4.34 8.79 9.24 8.16 9.89 -5.32%
DY 3.40 1.45 0.93 5.06 4.84 3.68 1.72 12.02%
P/NAPS 0.76 0.84 0.83 1.06 0.85 1.03 1.95 -14.52%
Price Multiplier on Announcement Date
31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 CAGR
Date 23/02/23 25/02/22 31/03/21 25/02/20 28/02/19 28/02/18 28/02/17 -
Price 1.62 1.68 1.70 1.78 1.62 1.65 3.23 -
P/RPS 1.83 2.65 2.28 1.80 1.45 1.48 1.36 5.06%
P/EPS 14.05 3.70 24.33 11.25 11.93 12.40 10.77 4.52%
EY 7.12 27.04 4.11 8.89 8.38 8.06 9.28 -4.31%
DY 3.40 1.49 0.88 5.11 4.40 3.64 1.61 13.26%
P/NAPS 0.76 0.82 0.87 1.05 0.94 1.04 2.08 -15.44%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment